|
SIGNIFICANT CONCENTRATIONS
|
12 Months Ended |
|---|---|
|
Dec. 31, 2013
|
|
| SIGNIFICANT CONCENTRATIONS | |
| SIGNIFICANT CONCENTRATIONS |
3. SIGNIFICANT CONCENTRATIONS For the year ended December 31, 2013, AZ and Daiichi accounted for 80% and 20% of our revenues, respectively. For the year ended December 31, 2012, AZ, Daiichi and BerGenBio accounted for 44%, 33% and 22% of our revenues, respectively. For the year ended December 31, 2011, Merck Serono and BerGenBio accounted for 89% and 11% of our revenues, respectively. At December 31, 2013, we had accounts receivable of $5.8 million from AZ. We had no accounts receivable at December 31, 2012. |
| X | ||||||||||
|
- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|